^
Association details:
| Biomarker: | CD79A mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Yinuokai (orelabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
Published date:
06/09/2023
Excerpt:
We aimed to analyze efficacy and safety of O plus R-CHOP-like (O+R-CHOP) for untreated non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) patients (pts)...5, 2, and 1 pt had detected MYD88, CD79A, and TP53 mutations, respectively....By subgroup analysis of 11 pts after induction stage...pts with MYD88 and CD79A mutations obtained CR of 80.0% and 100.0%, respectively among 10 pts with O+R-CHOP.
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.1002/hon.3165_659
Trial ID:
